The 25% decline in Centene’s stock seems warranted given the substantial earnings adjustment and ongoing ambiguity. With more state data still forthcoming and the threat of additional earnings ...

Centene Corporation (NYSE:CNC), ... Our Pro platform offers fair value estimates, performance predictions, and risk assessments, along with additional tips and expert analysis.

HBM, STNE, CNC, and CVS stand out for low P/CF ratios and strong value scores as investors seek quality in a cautious market.

Based on the estimated 2024 earnings forecast by a consensus of analysts of $6.75 to $6.84 times the PE of 11.42, Centene stock is selling at a fair value of over $78 per share.

Centene aims to be a top provider of government-sponsored health plans. Although it has grown at a solid clip organically, it also has made significant acquisitions—most notably WellCare in ...

Centene, a major insurer in Medicaid and ACA markets, beat Q1 estimates, raised guidance, and shows margin strength. See why CNC stock is a buy.

Centene aims to be the top provider of government-sponsored health plans. Although it has grown at a solid clip organically, Centene also has made significant acquisitions--most notably the 2020 ...

Centene has a Value Score of A. Shares of Centene have declined 15.1% in the past year. CVS Health , a leading health solutions company, carries a Zacks Rank #2. The company has a trailing four ...

Three-year partnership to increase value-based payment model adoption and improve maternal and child health outcomes in community health centers, impacting up to 1 in 5 Medicaid members CHCs ...

Over the past year, Centene has been hard at work on a value creation effort that aims to grow its core health plan businesses. | Centene is in the midst of a companywide value creation initiative.

Centene has agreed to sell Magellan Specialty Health to Evolent Health, the latest move in its broad value creation plan. The government insurer said in an announcement that it expects to bank ...